ES2738526T3 - Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos - Google Patents
Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos Download PDFInfo
- Publication number
- ES2738526T3 ES2738526T3 ES12781534T ES12781534T ES2738526T3 ES 2738526 T3 ES2738526 T3 ES 2738526T3 ES 12781534 T ES12781534 T ES 12781534T ES 12781534 T ES12781534 T ES 12781534T ES 2738526 T3 ES2738526 T3 ES 2738526T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- substituted
- unsubstituted
- solution
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](CC1)([C@](CC2)[C@@](CC3)[C@]1[C@@](CC1)[C@]3C[C@]1(C#CCl)O)[C@]2C(CS*)=O Chemical compound C[C@](CC1)([C@](CC2)[C@@](CC3)[C@]1[C@@](CC1)[C@]3C[C@]1(C#CCl)O)[C@]2C(CS*)=O 0.000 description 5
- BJGRFMVIXJYDHI-COVJHCGESA-N CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@@]1(COC)O)C2C(CO)=O Chemical compound CC(CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@@H]3C[C@@]1(COC)O)C2C(CO)=O BJGRFMVIXJYDHI-COVJHCGESA-N 0.000 description 1
- UMHMVRANVZYDNS-ZJGJLQLSSA-N CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CBr)=O Chemical compound CC(CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CBr)=O UMHMVRANVZYDNS-ZJGJLQLSSA-N 0.000 description 1
- LETMEIKVOWOVIE-GKEUNLPTSA-N CCC[C@@](C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1cncc1)=O)(COC)O Chemical compound CCC[C@@](C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1cncc1)=O)(COC)O LETMEIKVOWOVIE-GKEUNLPTSA-N 0.000 description 1
- SLHJGNMPRYDGCK-DDHVEKBHSA-N CCC[C@](C)(C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1nccn1)=O)O Chemical compound CCC[C@](C)(C[C@H](CC1)C[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C[n]1nccn1)=O)O SLHJGNMPRYDGCK-DDHVEKBHSA-N 0.000 description 1
- NOPMRWKAPOQHLJ-ZEFRRGKSSA-N C[C@@H](CC1)CC(CC2)[C@H]1C(CC1)C2C(CC2)[C@@]1(C)[C@H]2C(C)=O Chemical compound C[C@@H](CC1)CC(CC2)[C@H]1C(CC1)C2C(CC2)[C@@]1(C)[C@H]2C(C)=O NOPMRWKAPOQHLJ-ZEFRRGKSSA-N 0.000 description 1
- WXWCDZPOMIUNPM-CJRUCWEJSA-N C[C@@H](CC1)[C@@H](CC[C@@H](C2)CC=C[C@]2(O)OC)[C@H](CC2)[C@]1(C)[C@H]2C(C)=O Chemical compound C[C@@H](CC1)[C@@H](CC[C@@H](C2)CC=C[C@]2(O)OC)[C@H](CC2)[C@]1(C)[C@H]2C(C)=O WXWCDZPOMIUNPM-CJRUCWEJSA-N 0.000 description 1
- WHTAGOHJUYRPKE-OETXNUODSA-N C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C)=O Chemical compound C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(C)=O WHTAGOHJUYRPKE-OETXNUODSA-N 0.000 description 1
- NDYZXPKPZRWYJV-NQNAPEONSA-N C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CBr)=O Chemical compound C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CBr)=O NDYZXPKPZRWYJV-NQNAPEONSA-N 0.000 description 1
- YUYCUNPFXFPMMW-NQNAPEONSA-N C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CO)=O Chemical compound C[C@H](C1)[C@H](C[C@@](C)(CC2)O)[C@H]2[C@@H](CC2)[C@@H]1[C@H](CC1)[C@@]2(C)[C@H]1C(CO)=O YUYCUNPFXFPMMW-NQNAPEONSA-N 0.000 description 1
- NSGSGROCHJEOIK-BJZHTQEZSA-N C[C@H](CC1)[C@@H](CC[C@@](COC)(C2)O)[C@H]2CCC[C@H](CC2)C1(C)[C@H]2C(C)=O Chemical compound C[C@H](CC1)[C@@H](CC[C@@](COC)(C2)O)[C@H]2CCC[C@H](CC2)C1(C)[C@H]2C(C)=O NSGSGROCHJEOIK-BJZHTQEZSA-N 0.000 description 1
- UORBDGZWPNKERU-WKXDXTRLSA-N C[C@](CC1)([C@@H](C2)[C@H](CC3)[C@H]1C(CC[C@@](COC)(C1)O)[C@@]31N=C)C2Br Chemical compound C[C@](CC1)([C@@H](C2)[C@H](CC3)[C@H]1C(CC[C@@](COC)(C1)O)[C@@]31N=C)C2Br UORBDGZWPNKERU-WKXDXTRLSA-N 0.000 description 1
- SPZWQCAIQBFUOQ-SGJHKPSISA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@@]1(O)OC)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@@]1(O)OC)[C@H]2C(CO)=O SPZWQCAIQBFUOQ-SGJHKPSISA-N 0.000 description 1
- UVGUZLGBXVHUPV-HKHBUPFLSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=C)C21OCCO1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=C)C21OCCO1 UVGUZLGBXVHUPV-HKHBUPFLSA-N 0.000 description 1
- ZGISVRXPAWFDON-LXGGTWONSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=O)C21OCCO1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1C3=O)C21OCCO1 ZGISVRXPAWFDON-LXGGTWONSA-N 0.000 description 1
- MICWPNVHGQVWKU-KQBFAJRKSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1[C@H]3O)C21OCCO1 Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@@H](C1)OC(C)=O)[C@H]1[C@H]3O)C21OCCO1 MICWPNVHGQVWKU-KQBFAJRKSA-N 0.000 description 1
- ZRWGKZRIULCWMU-DZICADCFSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(C)=O ZRWGKZRIULCWMU-DZICADCFSA-N 0.000 description 1
- SZJSEMWMLTYQGH-NYBZHNPDSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CBr)=O SZJSEMWMLTYQGH-NYBZHNPDSA-N 0.000 description 1
- RHDNXUPWQGVYIA-NYBZHNPDSA-N C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](C3)[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1[C@@H]3F)[C@H]2C(CO)=O RHDNXUPWQGVYIA-NYBZHNPDSA-N 0.000 description 1
- LDIWEDPNAVDNSJ-YSLAPMGRSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1cncc1)=O LDIWEDPNAVDNSJ-YSLAPMGRSA-N 0.000 description 1
- HQJUHJWMHWEYBR-URDRGLOHSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C[n]1nccn1)=O HQJUHJWMHWEYBR-URDRGLOHSA-N 0.000 description 1
- ZIUUNICRKIQAKD-QRQKOEFOSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1cncc1)=O ZIUUNICRKIQAKD-QRQKOEFOSA-N 0.000 description 1
- TXCABTBXHSNKOJ-WWIDNNBLSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C#CCl)O)[C@H]2C(C[n]1nccn1)=O TXCABTBXHSNKOJ-WWIDNNBLSA-N 0.000 description 1
- JKRYNZRUWKBASC-RCSOYHDBSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C(F)F)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(C(F)F)O)[C@H]2C(C[n]1cncc1)=O JKRYNZRUWKBASC-RCSOYHDBSA-N 0.000 description 1
- XNUZAYHRYOOSFX-YRTSKKSESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1cncc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1cncc1)=O XNUZAYHRYOOSFX-YRTSKKSESA-N 0.000 description 1
- GLMMXZCVUUYNKR-CRGJMJCGSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(CF)O)[C@H]2C(C[n]1nccn1)=O GLMMXZCVUUYNKR-CRGJMJCGSA-N 0.000 description 1
- JIWJWZQRCFJBIU-QJCJHIBTSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C)=O JIWJWZQRCFJBIU-QJCJHIBTSA-N 0.000 description 1
- XNVUVEDLYYEQOS-YRTSKKSESA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1nccn1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@@H]3C[C@]1(COC)O)[C@H]2C(C[n]1nccn1)=O XNVUVEDLYYEQOS-YRTSKKSESA-N 0.000 description 1
- NTFXROHUKRNXEE-CLYQZSFASA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(C)=O NTFXROHUKRNXEE-CLYQZSFASA-N 0.000 description 1
- FQEQBPAQVZLYME-DCPTXXHLSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CC1CC1)O)[C@H]2C(CO)=O FQEQBPAQVZLYME-DCPTXXHLSA-N 0.000 description 1
- QMZLDCPSAVTNRY-DWZOGCISSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CCl)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C#CCl)O)[C@H]2C(CO)=O QMZLDCPSAVTNRY-DWZOGCISSA-N 0.000 description 1
- FRPFNZSDZDILPT-VCSUUWALSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CBr)=O FRPFNZSDZDILPT-VCSUUWALSA-N 0.000 description 1
- IDOZPADGFLFDRO-VCSUUWALSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C(F)F)O)[C@H]2C(CO)=O IDOZPADGFLFDRO-VCSUUWALSA-N 0.000 description 1
- VOZOMZWSLGQRKP-SMPVXYKMSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C)=O VOZOMZWSLGQRKP-SMPVXYKMSA-N 0.000 description 1
- JOEGIEGOLJKYIO-MEFKEFOCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC[C@@]14O)[C@@H]3C1C4(F)F)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC[C@@]14O)[C@@H]3C1C4(F)F)[C@H]2C(C)=O JOEGIEGOLJKYIO-MEFKEFOCSA-N 0.000 description 1
- KELRVUIFMYCLHB-MTLKIPAASA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@H](C1)O)C1=CC3)C2=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@H](C1)O)C1=CC3)C2=O KELRVUIFMYCLHB-MTLKIPAASA-N 0.000 description 1
- NXCBOIYBNCKRJS-WQUGUCIPSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@](C1)(C(F)F)O)C1=CC3)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@@](C1)(C(F)F)O)C1=CC3)[C@H]2C(C)=O NXCBOIYBNCKRJS-WQUGUCIPSA-N 0.000 description 1
- CBFHLGAYEQYENW-ZQXMCZQSSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(C)=O CBFHLGAYEQYENW-ZQXMCZQSSA-N 0.000 description 1
- JLBOUNFDCKLETJ-MTJVMKCNSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CBr)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CBr)=O JLBOUNFDCKLETJ-MTJVMKCNSA-N 0.000 description 1
- ZLKOAMQLQHOQPX-MTJVMKCNSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CO)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](C)(C1)O)[C@@H]1C(C)(C)C3)[C@H]2C(CO)=O ZLKOAMQLQHOQPX-MTJVMKCNSA-N 0.000 description 1
- ORHCHJPLWPHIJR-VNEVJAEPSA-N C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H]3[C@H]1[C@@H](CC[C@](COC)(C1)O)C1=CC3)[C@H]2C(C)=O ORHCHJPLWPHIJR-VNEVJAEPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547291P | 2011-10-14 | 2011-10-14 | |
| US201261698204P | 2012-09-07 | 2012-09-07 | |
| PCT/US2012/060136 WO2013056181A1 (en) | 2011-10-14 | 2012-10-12 | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2738526T3 true ES2738526T3 (es) | 2020-01-23 |
Family
ID=47143295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12781534T Active ES2738526T3 (es) | 2011-10-14 | 2012-10-12 | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20150291654A1 (https=) |
| EP (3) | EP4717314A2 (https=) |
| JP (5) | JP2014528485A (https=) |
| CN (4) | CN119192266A (https=) |
| AU (6) | AU2012323888A1 (https=) |
| CA (2) | CA3152410A1 (https=) |
| ES (1) | ES2738526T3 (https=) |
| PT (1) | PT2766380T (https=) |
| WO (1) | WO2013056181A1 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101583620B (zh) | 2005-11-28 | 2016-08-17 | 马里纳斯医药公司 | 加奈索酮组合物及其制备和使用方法 |
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| CN119192266A (zh) | 2011-10-14 | 2024-12-27 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| DK2925327T3 (da) | 2012-11-30 | 2024-03-25 | Univ California | Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| ES2807264T3 (es) * | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| JP6470258B2 (ja) * | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| WO2015010054A2 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2848823T3 (es) | 2013-08-23 | 2021-08-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| HRP20201126T1 (hr) * | 2014-05-29 | 2020-12-11 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| WO2015195967A1 (en) * | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| UY36305A (es) * | 2014-09-17 | 2016-04-29 | Prevacus Inc | Compuestos de esteroides c-20, sus composiciones y usos para tratar lesión cerebral traumática (tbi), que incluyen conmociones cerebrales. |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| US10577390B2 (en) * | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016123056A1 (en) | 2015-01-26 | 2016-08-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP4155314A1 (en) * | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20180311258A1 (en) * | 2015-04-10 | 2018-11-01 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| AU2016289965B2 (en) | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| PL3319611T3 (pl) | 2015-07-06 | 2021-07-12 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| MX382122B (es) | 2015-07-06 | 2025-03-13 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| EP3436022B1 (en) * | 2016-04-01 | 2022-03-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| EP4233861A3 (en) | 2016-08-11 | 2023-10-11 | Ovid Therapeutics, Inc. | Compositions for treatment of essential tremor |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| PT3519422T (pt) | 2016-09-30 | 2022-12-05 | Sage Therapeutics Inc | Oxisteróis substituídos em c7 e métodos como moduladores nmda |
| DK4105223T3 (da) * | 2016-10-18 | 2025-07-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| CA3041088C (en) | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2019075362A1 (en) * | 2017-10-12 | 2019-04-18 | Sage Therapeutics, Inc. | METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS |
| EP3720867A1 (en) | 2017-12-08 | 2020-10-14 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
| EP3728284B1 (en) | 2017-12-22 | 2024-08-21 | Sage Therapeutics, Inc. | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders |
| CN114656514B (zh) * | 2018-02-11 | 2024-05-14 | 江苏豪森药业集团有限公司 | 一种甾族类衍生物调节剂及其制备方法和应用 |
| EP3750909B1 (en) * | 2018-02-11 | 2025-03-05 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Steroid derivative regulators, method for preparing the same, and uses thereof |
| IL283629B2 (en) | 2018-12-05 | 2026-03-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of using them |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CN113195512A (zh) | 2018-12-21 | 2021-07-30 | 萨奇治疗股份有限公司 | 3.α.-羟基-17.β.-酰胺神经活性类固醇及其组合物 |
| CR20240234A (es) | 2019-05-31 | 2024-07-09 | Sage Therapeutics Inc | ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629) |
| CN114728012A (zh) | 2019-08-05 | 2022-07-08 | 马瑞纳斯制药公司 | 用于治疗癫痫持续状态的加奈索酮 |
| CN118027131A (zh) * | 2019-08-07 | 2024-05-14 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| WO2021113068A1 (en) * | 2019-12-05 | 2021-06-10 | Sparx Therapeutics, Inc. | Neuroactive steroids and compositions and methods thereof |
| JP7780431B2 (ja) | 2019-12-06 | 2025-12-04 | マリナス ファーマシューティカルズ， インコーポレイテッド | 結節性硬化症の治療での使用のためのガナキソロン |
| MX2022010620A (es) * | 2020-02-27 | 2022-11-30 | Brii Biosciences Inc | Profarmacos de esteroides neuroactivos. |
| KR20220157426A (ko) | 2020-03-25 | 2022-11-29 | 세이지 테라퓨틱스, 인크. | 호흡기 병태의 치료를 위한 작용제의 용도 |
| BR112024001518A2 (pt) | 2021-07-28 | 2024-04-30 | Sage Therapeutics Inc | Formas cristalinas de um esteroide neuroativo |
| CN119256000A (zh) * | 2022-06-09 | 2025-01-03 | 山东绿叶制药有限公司 | 19-去甲c3,3-二取代的c21-氮杂环取代类固醇及其使用方法 |
| WO2024059608A1 (en) | 2022-09-15 | 2024-03-21 | Sage Therapeutics, Inc. | Deuterated neuroactive steroids |
| KR20250162825A (ko) | 2023-03-14 | 2025-11-19 | 쿠리아 스페인, 에스.에이.유. | 3알파-하이드록시-3베타-알킬 스테로이드의 제조를 위한 방법 및 중간체 |
| WO2025119319A1 (zh) * | 2023-12-08 | 2025-06-12 | 山东绿叶制药有限公司 | 一种gabaa受体调节剂的晶型及其制备方法和应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1994E (fr) | 1902-11-20 | 1903-11-24 | Jules Bernard | Dispositif de suspension élastique amortisseur de chocs pour chassis, caisses de véhicules, sièges et sommiers élastiques |
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1380246A (en) | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| GB1436324A (en) | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) * | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| AU609927B2 (en) * | 1987-08-25 | 1991-05-09 | Kelvin W. Gee | Compositions and methods for alleviating stress, anxiety and seizure activity |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| AU698834B2 (en) * | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| KR100338287B1 (ko) | 1994-02-14 | 2002-11-30 | 푸르듀 파머 리미티드 | 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난 |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| AU3125695A (en) | 1994-07-21 | 1996-02-22 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| FI972202L (fi) * | 1994-11-23 | 1997-07-17 | Cocensys Inc | Androstaanit ja pregnaanit GABA-reseptoreiden allosteeriseen muunteluun |
| RU2194712C2 (ru) | 1995-06-06 | 2002-12-20 | Коукенсис, Инк. | НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР |
| AU3967297A (en) * | 1996-08-01 | 1998-02-25 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| UA73736C2 (en) | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| ATE297406T1 (de) | 2000-02-18 | 2005-06-15 | Taiho Pharmaceutical Co Ltd | Verfahren zur herstellung von steroid-derivaten |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| DE60128251T2 (de) | 2000-11-03 | 2008-01-10 | Washington University | Östronderivate mit zellschützender wirkung |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| ES2339450T3 (es) | 2003-03-24 | 2010-05-20 | Sterix Limited | Derivados de estrogenos como inhibidores de esteroide sulfatasa. |
| WO2005000869A1 (en) | 2003-05-29 | 2005-01-06 | Washington University | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| WO2005051972A1 (en) | 2003-11-24 | 2005-06-09 | Merck & Co., Inc. | Estrogen receptor modulators |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| AU2005330504B2 (en) | 2004-09-29 | 2010-10-28 | Harbor Biosciences, Inc. | Steroid analogs and characterization and treatment methods |
| RS51304B (sr) | 2005-06-09 | 2010-12-31 | Euro-Celtique S.A. | Farmaceutske kompozicije neuroaktivnog steroida i njihova upotreba |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| WO2008157460A1 (en) | 2007-06-15 | 2008-12-24 | Cook, Kevin, M. | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ301216B6 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| AU2011284606A1 (en) | 2010-07-30 | 2013-03-14 | Pharmacellion Ltd | Compounds and methods for treating neoplasia |
| US20120214987A1 (en) | 2010-12-15 | 2012-08-23 | Yu Ge | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| WO2012109752A1 (en) | 2011-02-15 | 2012-08-23 | Socpra Sciences Et Génie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| WO2012116290A2 (en) | 2011-02-25 | 2012-08-30 | Washington University | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| ES2657986T3 (es) | 2011-03-23 | 2018-03-07 | Etsuro Ito | Método y kit para la medición de muy alta sensibilidad de proteína y ácido nucleico y un novedoso sustrato enzimático |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| CN119192266A (zh) | 2011-10-14 | 2024-12-27 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2014071449A1 (en) | 2012-11-09 | 2014-05-15 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| MX365644B (es) | 2012-12-18 | 2019-06-10 | Univ Washington | Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos. |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| ES2807264T3 (es) | 2013-04-17 | 2021-02-22 | Sage Therapeutics Inc | Esteroides neuroactivos 19-nor para métodos de tratamiento |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| JP6470258B2 (ja) | 2013-04-17 | 2019-02-13 | セージ セラピューティクス， インコーポレイテッド | １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| WO2015010054A2 (en) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2848823T3 (es) | 2013-08-23 | 2021-08-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| HRP20201126T1 (hr) | 2014-05-29 | 2020-12-11 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, njihovi pripravci i uporabe |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10577390B2 (en) | 2014-10-16 | 2020-03-03 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| ME03809B (me) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2016123056A1 (en) | 2015-01-26 | 2016-08-04 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| US20180250313A1 (en) | 2015-09-08 | 2018-09-06 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| EP3377070A4 (en) | 2015-11-20 | 2019-07-10 | Sage Therapeutics, Inc. | COMPOUNDS AND METHOD FOR THEIR USE |
| HK1258616A1 (zh) | 2016-03-08 | 2019-11-15 | Sage Therapeutics, Inc. | 神经活性类固醇、组合物、及其用途 |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| US20190233465A1 (en) | 2016-07-11 | 2019-08-01 | Sage Therapeutics, Inc. | C7, c12, and c16 substituted neuroactive steroids and their methods of use |
| TWI904593B (zh) | 2016-08-23 | 2025-11-11 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| WO2019045121A1 (en) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | TREATMENT OF CNS DISEASES |
-
2012
- 2012-10-12 CN CN202411226456.XA patent/CN119192266A/zh active Pending
- 2012-10-12 WO PCT/US2012/060136 patent/WO2013056181A1/en not_active Ceased
- 2012-10-12 CA CA3152410A patent/CA3152410A1/en active Pending
- 2012-10-12 EP EP25222656.8A patent/EP4717314A2/en active Pending
- 2012-10-12 US US14/351,449 patent/US20150291654A1/en not_active Abandoned
- 2012-10-12 CN CN201810869360.3A patent/CN108976272B/zh active Active
- 2012-10-12 AU AU2012323888A patent/AU2012323888A1/en not_active Abandoned
- 2012-10-12 JP JP2014535962A patent/JP2014528485A/ja not_active Withdrawn
- 2012-10-12 ES ES12781534T patent/ES2738526T3/es active Active
- 2012-10-12 EP EP12781534.8A patent/EP2766380B1/en active Active
- 2012-10-12 CN CN201280060883.4A patent/CN104136452A/zh active Pending
- 2012-10-12 CA CA2852057A patent/CA2852057C/en active Active
- 2012-10-12 EP EP19169283.9A patent/EP3572417B1/en active Active
- 2012-10-12 CN CN202110494113.1A patent/CN113234114A/zh active Pending
- 2012-10-12 PT PT12781534T patent/PT2766380T/pt unknown
-
2017
- 2017-07-26 AU AU2017208284A patent/AU2017208284B2/en active Active
- 2017-08-21 US US15/681,983 patent/US10435431B2/en active Active
- 2017-12-07 JP JP2017235371A patent/JP6745783B2/ja active Active
-
2019
- 2019-04-30 AU AU2019203046A patent/AU2019203046B2/en active Active
- 2019-08-22 US US16/548,248 patent/US20200223884A1/en not_active Abandoned
-
2020
- 2020-08-04 JP JP2020132282A patent/JP7096864B2/ja active Active
- 2020-10-22 US US17/077,025 patent/US20210040141A1/en not_active Abandoned
-
2021
- 2021-07-08 AU AU2021204782A patent/AU2021204782B2/en active Active
-
2022
- 2022-06-24 JP JP2022101881A patent/JP7617057B2/ja active Active
- 2022-10-19 US US17/969,105 patent/US20230287037A1/en not_active Abandoned
-
2023
- 2023-06-26 AU AU2023204015A patent/AU2023204015B2/en active Active
-
2025
- 2025-01-06 JP JP2025001804A patent/JP2025061026A/ja active Pending
- 2025-12-09 AU AU2025279604A patent/AU2025279604A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2738526T3 (es) | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos | |
| AU2025203873A1 (en) | Neuroactive steroids, compositions, and uses thereof | |
| WO2013188792A2 (en) | Neuroactive steroids, compositions, and uses thereof | |
| HK40018206A (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK1201274B (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK40120913A (zh) | 3，3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 | |
| HK40001824A (en) | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof | |
| HK40001824B (zh) | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |